39 Central Indiana Corporations Spent $650 Million in 2020

This three-part webinar series reviews the key considerations for design and conduct of a development plan for a monoclonal antibody (mAb) product.

Bringing a drug from discovery to market is an expensive and time-consuming business. Every drug that fails comes with a cost which could be both reputational and financial. Keeping your development program on track is therefore critical to success.

Pharmaceutical development is inherently risky. To develop a molecule that has a desired, efficacious, but safe, effect in humans is a remarkable achievement considering the statistics.